SEC Tracker
Get the app

Passage BIO PASG

Passage BIO Q3 FY23: net loss $27.1M; diluted EPS −$9.80

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q
Exhibit 10.1
Material contract
Exhibit 10.2
Material contract

Key figures from this report

These are the numbers Passage BIO reported for Q3 FY23, the quarter ended Sep 30, 2023, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$27.1MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Diluted EPS−$9.80No year-earlier figure tagged. Split-adjusted, as the tables show it; the filing reported −$0.4910-Q income statement, on EDGAR
  3. Cash and cash equivalents$33.6MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
  4. Cash from operations−$19.2MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Passage BIO files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Pulmatrix PULM public float $25M, Jun 30, 2025
  2. Scynexis SCYX public float $26M, Jun 30, 2025
  3. Palatin Technologies PTN public float $26M, Dec 31, 2025
  4. Curis CRIS public float $25M, Jun 30, 2025
  5. Kala Bio KALA public float $25M, Jun 30, 2025